Ali Assefi, MD
Nephrology · Fairfax, VANPI 1275531832
Payments from drug & device makers
Across 382 payments — averaging $790.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$170K
- AstraZeneca$73K
- Bayer$23K
- Novo Nordisk$12K
- Boehringer Ingelheim$6K
- Travere Therapeutics, Inc.$6K
- plus $12K from 29 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 43 | $169,828 |
| AstraZeneca(2 entities) | 53 | $72,524 |
| Bayer | 30 | $22,755 |
| Novo Nordisk | 10 | $11,912 |
| Boehringer Ingelheim | 11 | $6,397 |
| Travere Therapeutics, Inc. | 16 | $6,382 |
| AbbVie | 1 | $3,670 |
| Lilly USA, LLC | 8 | $2,542 |
| Amgen(2 entities) | 30 | $1,494 |
| Otsuka America Pharmaceutical, Inc. | 24 | $649 |
| ANI Pharmaceuticals, Inc. | 18 | $451 |
| Novartis | 29 | $442 |
| Mallinckrodt Hospital Products Inc. | 14 | $426 |
| Aurinia Pharma U.S., Inc. | 12 | $317 |
| Exthera Medical Corporation | 2 | $265 |
| Ardelyx, Inc. | 9 | $253 |
| Akebia Therapeutics Inc | 11 | $248 |
| Calliditas Therapeutics US Inc. | 10 | $197 |
| OPKO Pharmaceuticals, LLC | 8 | $179 |
| Vifor Pharma, Inc. | 8 | $164 |
| Mallinckrodt Enterprises LLC | 3 | $152 |
| Scpharmaceuticals Inc. | 6 | $145 |
| Fresenius USA Marketing, Inc. | 7 | $136 |
| Kyowa Kirin, Inc. | 4 | $94 |
| Baxter Healthcare | 1 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Genentech USA, Inc. | 2 | $45 |
| Biomerieux Inc | 2 | $30 |
| Cormedix Inc. | 1 | $30 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Recor Medical Inc | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$301,977 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Fairfax
- Ahmadshah MirkhelFairfax$902K
- Renuka SothinathanFairfax$617K
- Reza ZonoziFairfax$482K
- Kinjal PatelFairfax$31K
- Gregory WangFairfax$30K
- Renu Regunathan-ShenkFairfax$22K
- Paul ModlingerFairfax$18K
- Magnus IkhinmwinFairfax$11K
- Olayiwola AyodejiHampton$7M
- Kiranjit DhillonNorfolk$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.